Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) had its target price hoisted by equities researchers at Morgan Stanley from $7.00 to $8.00 in a report issued on Monday, Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley‘s price objective would indicate a potential upside of 86.31% from the company’s previous close.
A number of other equities analysts also recently weighed in on the stock. Wall Street Zen raised shares of Atea Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atea Pharmaceuticals in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $8.00.
View Our Latest Stock Report on Atea Pharmaceuticals
Atea Pharmaceuticals Stock Down 0.1%
Shares of AVIR stock traded down $0.01 during trading hours on Monday, hitting $4.29. 12,433 shares of the company were exchanged, compared to its average volume of 379,796. The firm has a market cap of $344.83 million, a PE ratio of -2.20 and a beta of 0.76. Atea Pharmaceuticals has a 1 year low of $2.92 and a 1 year high of $6.45. The firm has a fifty day moving average of $4.79 and a 200 day moving average of $4.94.
Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.11. Analysts expect that Atea Pharmaceuticals will post -1.91 earnings per share for the current year.
Hedge Funds Weigh In On Atea Pharmaceuticals
Large investors have recently modified their holdings of the company. Legal & General Group Plc purchased a new stake in shares of Atea Pharmaceuticals during the second quarter worth about $33,000. Quantinno Capital Management LP purchased a new position in Atea Pharmaceuticals in the first quarter valued at about $86,000. Spark Investment Management LLC purchased a new position in Atea Pharmaceuticals in the second quarter valued at about $75,000. Headlands Technologies LLC purchased a new position in Atea Pharmaceuticals in the second quarter valued at about $77,000. Finally, Engineers Gate Manager LP acquired a new stake in Atea Pharmaceuticals during the 2nd quarter valued at approximately $78,000. 86.67% of the stock is currently owned by hedge funds and other institutional investors.
Atea Pharmaceuticals Company Profile
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral diseases. Its research centers on compounds intended to interfere with viral replication. The company’s investigational portfolio has included bemnifosbuvir, an oral antiviral candidate studied for COVID-19, as well as programs targeting other viral infections, including dengue. These medicines are investigational and are not established marketed treatments.
Featured Articles
- Five stocks we like better than Atea Pharmaceuticals
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
